Rheumatoid arthritis and other rheumatic diseases lead to considerable morbidity, and also impact mortality. Efficacious modern anti-rheumatic therapies and treatment regimens holds the promise of reducing the burden of rheumatic diseases, ultimately also or reducing the otherwise increased mortality. This talk aims at summarizing the available data on mortality in rheumatic diseases (level of increase? reasons? secular trends? predictors?) and the relation between anti-rheumatic therapies and mortality (increase? decrease? shifts in causes of deaths?), and to dissect some of the methodological issues complicating analyses of mortality in relation to specific treatments. Mortality data from observational cohorts, randomized trials, and from drug registers will be reviewed, and put into context.
Disclosure of Interest None Declared